A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Inclusion Criteria:

   - progressive, recurrent or refractory Ewing's sarcoma, or recurrent or refractory
   osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following
   sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor,
   extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma;

   - Cohort 3 only: age must be >= 2 and <= 21 years

Exclusion Criteria:

   - clinically significant unrelated systemic illness which would compromise the
   participant's ability to tolerate the investigational agent, or interfere with the
   study procedures or results;

   - known hypersensitivity to any of the components of R1507 or prior hypersensitivity
   reactions to monoclonal antibodies;

   - treatment (within the past 2 weeks) with pharmacologic doses of corticosteroids or
   other immunosuppressive agents;

   - current or prior therapy with insulin-like growth factor (IGF) inhibitor (monoclonal
   or specific kinase inhibitor);

   - history of solid organ transplant;

   - other malignant disease diagnosed within the previous 5 years, excluding
   intra-epithelial cervical neoplasia or non-melanoma skin cancer;

   - active central nervous system disease